.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Fuji
Julphar
Boehringer Ingelheim
Fish and Richardson
Accenture
Deloitte
Express Scripts
Chubb

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 070433

« Back to Dashboard

NDA 070433 describes FUROSEMIDE, which is a drug marketed by Abraxis Pharm, Accord Hlthcare, Amneal Pharms Co, Astrazeneca, Baxter Hlthcare Corp, Emcure Pharms Ltd, Fresenius Kabi Usa, Hospira, Igi Labs Inc, Intl Medication, Luitpold, Marsam Pharms Llc, Smith And Nephew, Warner Chilcott, Watson Labs, West-ward Pharms Int, Wockhardt, Wyeth Ayerst, Dava Pharms Inc, Ipca Labs Ltd, Ivax Sub Teva Pharms, Kalapharm, Leading Pharma Llc, Mylan, Prinston Inc, Sandoz, Sun Pharm Inds Inc, Sun Pharm Industries, Superpharm, and Watson Labs Teva, and is included in fifty-seven NDAs. It is available from sixty-one suppliers. Additional details are available on the FUROSEMIDE profile page.

The generic ingredient in FUROSEMIDE is furosemide. There are twenty-one drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the furosemide profile page.

Summary for 070433

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 070433

Medical Subject Heading (MeSH) Categories for 070433

Suppliers and Packaging for NDA: 070433

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FUROSEMIDE furosemide SOLUTION;ORAL 070433 ANDA West-Ward Pharmaceuticals Corp. 0054-3298 0054-3298-63 500 mL in 1 BOTTLE, PLASTIC (0054-3298-63)
FUROSEMIDE furosemide SOLUTION;ORAL 070433 ANDA Atlantic Biologicals Corps 17856-3298 17856-3298-1 5 mL in 1 CUP (17856-3298-1)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength40MG/5ML
Approval Date:Apr 22, 1987TE:RLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Express Scripts
Deloitte
McKinsey
Cerilliant
Baxter
Healthtrust
Chubb
Queensland Health
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot